Structure Therapeutics (GPCR) Leerink Global Healthcare Conference 2025 summary

Strategic focus and platform

• Emphasis on making medicines more accessible by converting biologics and peptides into oral small molecules.

• Lead program is a GLP-1 oral small molecule, with a major breakthrough anticipated in 2025.

• Positive phase IIa data showed strong weight loss and low discontinuation rates.

• Two phase IIb studies (ACCESS and ACCESS II) are ongoing, targeting different dosages and set to read out in Q4 2025.

• Pipeline includes GLP-1, Amylin, GIP, GCG, and Apelin programs, with a focus on fixed-dose combinations.

Differentiation and intellectual property

• Aleniglipron is based on the orforglipron (Chugai) scaffold, preferred for its potency and safety profile.

• Manufacturing improvements include removal of chiral centers and enhanced safety, with strong preclinical safety data.

• Aggressive IP strategy has resulted in more patents in GLP-1 and Amylin small molecules than competitors.

• Ongoing monitoring of global patent literature to maintain IP leadership.

Clinical development and trial design

• ACCESS and ACCESS II phase IIb studies have completed enrollment and will report results in Q4 2025.

• Efficacy bar is set to match or exceed peptide standards, with tolerability being a key focus.

• Extended-release and modified formulations are in development to address tolerability for sensitive populations.

• Updates on formulation studies expected in 2025.